Ventus Therapeutics US Inc. patents describe new cyclic GMP-AMP synthase (MB21D1; cGAS) inhibitors potentially useful for the treatment of autoimmune disease, rheumatic diseases and liver diseases, among others.
In what represents the first patenting from Glasgow-based Microplate Dx Ltd., three of its co-founders describe a system for diagnosing microbial infections and performing rapid antimicrobial susceptibility testing, enabling quicker and more precise determination of effective antibiotics.
Leal Therapeutics Inc. has divulged mitochondrial glutaminase kidney isoform (GLS, GLS1) inhibitors reported to be useful for the treatment of neurological and psychiatric disorders.
Nain Biotech (Hangzhou) Co. Ltd. has identified tetrahydrocarbazole derivatives reported to be useful for the treatment of cancer and viral infections.
Foghorn Therapeutics Inc. has disclosed proteolysis targeting chimera (PROTAC) compounds comprising ubiquitin ligase binding moieties covalently linked to a probable global transcription activator SNF2L2 (SMARCA2; BAF190B; SNF2-α) and/or transcription activator BRG1 (SMARCA4; BAF190A; SNF2-β) targeting moiety reported to be useful for the treatment of cancer and viral infection.
Scientists at Inventisbio Co. Ltd. and Inventisbio LLC have divulged E3 ubiquitin-protein ligase CBL-B (CBLB) inhibitors reported to be useful for the treatment of cancer.
TYK Medicines Inc. has identified proteolysis targeting chimera (PROTAC) compounds comprising an E3 ubiquitin ligase-binding moiety covalently bonded to an EGFR (mutant)-targeting moiety through a linker.
RSS
